Short Interest in Bayer Aktiengesellschaft (OTCMKTS:BAYRY) Rises By 42.3%

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) saw a significant increase in short interest in the month of May. As of May 31st, there was short interest totalling 223,200 shares, an increase of 42.3% from the May 15th total of 156,900 shares. Based on an average daily volume of 2,505,100 shares, the short-interest ratio is presently 0.1 days.

Bayer Aktiengesellschaft Stock Performance

Shares of Bayer Aktiengesellschaft stock traded down $0.13 on Friday, hitting $7.24. 287,468 shares of the company traded hands, compared to its average volume of 1,136,538. The firm’s 50-day simple moving average is $7.52 and its 200 day simple moving average is $7.97. The company has a debt-to-equity ratio of 1.06, a quick ratio of 0.80 and a current ratio of 1.31. Bayer Aktiengesellschaft has a 12-month low of $6.96 and a 12-month high of $14.70.

Bayer Aktiengesellschaft (OTCMKTS:BAYRY) last posted its quarterly earnings data on Tuesday, May 14th. The company reported $0.77 earnings per share for the quarter. The firm had revenue of $14.95 billion for the quarter. Bayer Aktiengesellschaft had a negative net margin of 6.70% and a positive return on equity of 17.57%. On average, analysts expect that Bayer Aktiengesellschaft will post 1.36 EPS for the current year.

Bayer Aktiengesellschaft Cuts Dividend

The business also recently disclosed a dividend, which was paid on Monday, May 13th. Stockholders of record on Tuesday, April 30th were given a dividend of $0.0191 per share. The ex-dividend date of this dividend was Monday, April 29th. Bayer Aktiengesellschaft’s dividend payout ratio (DPR) is currently -2.30%.

Wall Street Analysts Forecast Growth

BAYRY has been the topic of several research reports. The Goldman Sachs Group began coverage on shares of Bayer Aktiengesellschaft in a research report on Thursday, May 30th. They issued a “neutral” rating on the stock. Sanford C. Bernstein reaffirmed a “market perform” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, March 7th. Finally, Citigroup reaffirmed a “neutral” rating on shares of Bayer Aktiengesellschaft in a report on Thursday, February 29th. One research analyst has rated the stock with a sell rating and nine have assigned a hold rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Hold”.

About Bayer Aktiengesellschaft

Bayer Aktiengesellschaft, together its subsidiaries, operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, and Crop Science segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and digital solutions, and contrast agents, as well as cell and gene therapy.